Recombinant Human FGFR-3/JTK4/CD333 (V555M) Protein was resolved with SDS-PAGE under reducing (Lane 1) and non-reducing (Lane 2) conditions.
The activity of FGFR3 is based on the MSA technology, and the content and ratio of the substrate and the product are directly separated and detected in real time and dynamically by the different migration rates of the substrate and the product after the enzymatic reaction.
FGFR3 also known as CD333 is a member of the fibroblast growth factor receptor (FGFR) family, which includes FGFR1-4, and FGFRL1. FGFR1-4 are cell surface membrane receptors that possess tyrosine kinase activity. FGFR3 plays a role in bone growth by regulating ossification. Gain of function mutations in FGFR3 inhibits chondrocyte proliferation and underlies achondroplasia and hypochondroplasia. FGFR3 inhibitors are in early clinical trials as a cancer treatment, e.g. BGJ398 for urothelial carcinoma. The FGFR3 receptor has a tyrosine kinase signaling pathway that is associated with many biological developments embryonically and in tissues. Studying the tyrosine kinase signaling pathway that FGFR3 displays has played a crucial role in the development of research of several cell activities.
